title: Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP.
abstract: A web-based application patient follow-up program was developed to create a registry of patients with ankylosing spondylitis (AS) by the Turkiye Romatizma Arastirma Savas Dernegi (TRASD) AS Study Group. This study describes the methodological background and patient characteristics. The patient follow-up program is a web-based questionnaire, which contains sections on socio-demographic data, anamnesis, personal and family history, systemic and musculoskeletal examination, laboratory and imaging data and treatment. Between October 1, 2007 and February 28, 2009, 1,381 patients from 41 centers were included in the registry (1,038 males [75.2%]; mean age 39.5 ± 10.7 years). Mean disease duration was 12.1 ± 8.5 years, and mean time from initial symptom to diagnosis was 5 ± 6.8 years (median 2 years). HLA-B27 positivity was detected in 73.7% of 262 patients tested. Manifestations of extraarticular involvement were anterior uveitis (13.2%), psoriasis and other skin and mucous membrane lesions (6%) and inflammatory bowel disease (3.8%). The prevalence of peripheral arthritis was 11.2%. In 51.7% of patients, the Bath AS Disease Activity Index was ≥4. But since our patients consisted of the ones with more severe disease who referred to the tertiary centers and needed a regular follow-up, they may not represent the general AS population. Disease-modifying anti-rheumatic drugs were being used by 41.9% of patients, with 16.4% using anti-TNF agents. TRASD-IP (Izlem Programi: Follow-up program) is the first AS registry in Turkey. Such databases are very useful and provide a basis for data collection from large numbers of subjects. TRASD-IP gives information on the clinical and demographic profiles of patients, and the efficacy and safety of anti-TNF drugs, examines the impact on quality of life, and provides real-life data that may be used in cost-effectiveness analyses.
authors: Ankara Numune Training & Research Hospital, Mürsel Uluç M, 937 S, No: 35/17, 06450 Ankara, Turkey. haticebodur@gmail.com
authors: Hatice
authors: H
authors: Bodur
authors: Sebnem
authors: S
authors: Ataman
authors: Derya Soy
authors: DS
authors: Buğdaycı
authors: Aylin
authors: A
authors: Rezvani
authors: Kemal
authors: K
authors: Nas
authors: Kaan
authors: K
authors: Uzunca
authors: Emel
authors: E
authors: Emlakçıoğlu
authors: Altınay Göksel
authors: AG
authors: Karatepe
authors: Bekir
authors: B
authors: Durmuş
authors: Melek
authors: M
authors: Sezgin
authors: Figen
authors: F
authors: Ayhan
authors: Pelin
authors: P
authors: Yazgan
authors: Tuncay
authors: T
authors: Duruöz
authors: Mahmut
authors: M
authors: Yener
authors: Alev
authors: A
authors: Gürgan
authors: Mehmet
authors: M
authors: Kırnap
authors: Engin
authors: E
authors: Cakar
authors: Lale
authors: L
authors: Altan
authors: Raikan
authors: R
authors: Soydemir
authors: Erhan
authors: E
authors: Capkın
authors: Ibrahim
authors: I
authors: Tekeoğlu
authors: Gülümser
authors: G
authors: Aydın
authors: Zafer
authors: Z
authors: Günendi
authors: Barış
authors: B
authors: Nacır
authors: Ali
authors: A
authors: Sallı
authors: Cihat
authors: C
authors: Oztürk
authors: Asuman
authors: A
authors: Memiş
authors: Yasemin
authors: Y
authors: Turan
authors: Erkan
authors: E
authors: Kozanoğlu
authors: Konçuy
authors: K
authors: Sivrioğlu
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000453:epidemiology; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020407:Internet; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011788:Quality of Life; D012042:Registries; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014421:Turkey / Q000453:epidemiology
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha